{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+2&page=11",
    "query": {
      "intervention": "Control Vaccine 2",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 680,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+2&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+2&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T12:42:33.889Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02935686",
      "title": "A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ad26.Mos4.HIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Clade C gp140 plus adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Clade C gp140/Mosaic gp140 plus adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "gp140 HIV Bivalent Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2017-03-31",
      "completion_date": "2023-11-22",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-10-17T12:42:33.889Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02935686"
    },
    {
      "nct_id": "NCT03480763",
      "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "V114",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PNEUMOVAX™23",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 652,
      "start_date": "2018-06-22",
      "completion_date": "2019-12-23",
      "has_results": true,
      "last_update_posted_date": "2021-11-02",
      "last_synced_at": "2026-10-17T12:42:33.889Z",
      "location_count": 15,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Spring Valley, California + 12 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03480763"
    },
    {
      "nct_id": "NCT07742644",
      "title": "A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Measles",
        "Mumps",
        "Rubella",
        "Varicella (Chickenpox)",
        "Measles-Mumps-Rubella+Chickenpox Vaccine"
      ],
      "interventions": [
        {
          "name": "MMRVNS vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMRV vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DTaP-IPV vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "4 Years to 6 Years"
      },
      "enrollment_count": 1860,
      "start_date": "2026-08-11",
      "completion_date": "2028-11-21",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-17T12:42:33.889Z",
      "location_count": 38,
      "location_summary": "Jonesboro, Arkansas • Little Rock, Arkansas • Huntington Park, California + 32 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07742644"
    },
    {
      "nct_id": "NCT00546585",
      "title": "Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza A/H7N7 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 126,
      "start_date": "2008-03",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2013-08-23",
      "last_synced_at": "2026-10-17T12:42:33.889Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00546585"
    },
    {
      "nct_id": "NCT01954251",
      "title": "Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Herpes Zoster"
      ],
      "interventions": [
        {
          "name": "Herpes Zoster vaccine GSK 1437173A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 829,
      "start_date": "2013-10-03",
      "completion_date": "2015-03-20",
      "has_results": true,
      "last_update_posted_date": "2018-05-02",
      "last_synced_at": "2026-10-17T12:42:33.889Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Carnegie",
          "state": "Pennsylvania"
        },
        {
          "city": "Erie",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01954251"
    },
    {
      "nct_id": "NCT03755713",
      "title": "A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "ASP0892",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 20,
      "start_date": "2019-03-12",
      "completion_date": "2021-10-11",
      "has_results": false,
      "last_update_posted_date": "2024-10-23",
      "last_synced_at": "2026-10-17T12:42:33.889Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03755713"
    },
    {
      "nct_id": "NCT02256488",
      "title": "Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prophylaxis: Influenza"
      ],
      "interventions": [
        {
          "name": "TIVc_LOT A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TIVc_LOT B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TIVc_LOT C",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TIVf",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 1561,
      "start_date": "2014-09",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2019-06-11",
      "last_synced_at": "2026-10-17T12:42:33.889Z",
      "location_count": 24,
      "location_summary": "Anaheim, California • Redding, California • San Diego, California + 19 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02256488"
    },
    {
      "nct_id": "NCT00851786",
      "title": "Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Herpes Zoster",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "ZOSTAVAX",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 395,
      "start_date": "2009-04-29",
      "completion_date": "2012-01-03",
      "has_results": true,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-17T12:42:33.889Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00851786"
    },
    {
      "nct_id": "NCT03814590",
      "title": "A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV Vaccine (GSK3844766A) unadjuvanted low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) unadjuvanted medium dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) unadjuvanted high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Saline solution)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1053,
      "start_date": "2019-01-21",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2022-08-05",
      "last_synced_at": "2026-10-17T12:42:33.889Z",
      "location_count": 18,
      "location_summary": "Jacksonville, Florida • Miami, Florida • Stockbridge, Georgia + 15 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03814590"
    },
    {
      "nct_id": "NCT07166770",
      "title": "Community-Led COVID-19 Testing Intervention to Address Mistrust",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COVID-19",
        "Trust"
      ],
      "interventions": [
        {
          "name": "Community-led discussion",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Old Dominion University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2025-07-01",
      "completion_date": "2026-01-27",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-17T12:42:33.889Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07166770"
    }
  ]
}